Clinical Trials

The G207 therapy consists of a single infusion directly into the tumor. The immunotherapy approach causes direct tumor cell death and also recruits immune system cells to aid the body’s own natural tumor defenses.

Completed

Phase 1 Study in 12 pediatric patients with recurrent high grade glioma (HGG)

  • Improved overall survival 12.2 months versus 5.6 months for historical trials
  • Dramatic Safety Advantage - No serious adverse events
  • Evidence of florid T-cell response in treated tumors turning immunologically “cold” tumors “hot”
  • Original Article "Oncolytic HSV-1 G207 Immunotherapy for Pediatric High-Grade Glioamas" (Friedman GK) published in New England Journal of Medicine April 10, 2021
[NCT02457845] »

Planned 2021

Phase 2 Clinical Trial of G207 in Children with Recurrent High-Grade Glioma

  • 30 children with recurrent glioma
  • Overall Survival measured against historical controls from prior pediatric HGG studies
  • Safety, immune response, and radiographic responses also will be evaluated
[NCT04482933] »

Enrolling

Phase 1 Study of G207 in combination with 5Gy radiation in up to 15 patients with recurrent medulloblastoma and other cerebellar tumors.

Other Planned Studies

Pediatric Combination Therapy Trials

Phase 1

  • G207, 5Gy radiation with 1 vs 2 Checkpoint Inhibitors: Phase 1  
  • G207, 5Gy radiation with low dose temozolomide: Phase 1  

Newly Diagnosed Pediatric Patients

Phase 1

  • Glioblastoma:  G207 + 5Gy radiation; 3 week pause then 2Gy radiation attenuated fractions (15 instead of 30) with concurrent low dose temozolomide (70mg/M2).
  • Glioblastoma: Multiple G207 doses with 5Gy radiation.  
  • Medulloblastoma - G207 therapy in combination with 5Gy Radiation